genedrive

Advancing Molecular Diagnostics to the Point of Care

Interim Results, Dec-21

29 March 2022

DOCUMENT INFORMATION

NOT FOR PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. This document, which comprises a presentation of the results for the period ending 31 December 2021, has been prepared by genedrive PLC ("genedrive"). By reviewing this presentation you agree to be bound by the following conditions. The release, presentation, publication or distribution of this presentation, in whole or in part, in certain jurisdictions may be restricted by law or regulation and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

No representation or warranty (express or implied) of any nature is given nor is any responsibility or liability of any kind accepted by genedrive or any of its directors, officers, employees, advisers, representatives or other agents, with respect to the truthfulness, completeness or accuracy of any information, projection, representation or warranty (express or implied), omissions, errors or misstatements in this presentation, or any other written or oral statement provided. None of genedrive or its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this material or otherwise in connection with this material.

Nothing contained in this presentation is intended to constitute an invitation or inducement to engage in investment activity for the purposes of the prohibition on financial promotions in section 21 of the UK Financial Services and Markets Act 2000. In making this presentation available, genedrive makes no recommendation to buy, sell or otherwise deal in shares of genedrive or in any other securities or investments whatsoever and does not constitute or form part of any offer, or an invitation to sell or issue or subscribe for or purchase any securities in nor of genedrive and you should neither rely nor act upon, directly or indirectly, any of the information contained in this presentation in respect of any such investment activity. Further, it should not be treated as giving investment, legal, accounting, regulatory, taxation or other advice.

Any recipients of this presentation outside the UK should inform themselves of and observe any applicable legal or regulatory requirements in their jurisdiction, and are treated as having represented that they are able to receive this presentation without contravention of any law or regulation in the jurisdiction in which they reside or conduct business. In particular, the securities referred to in this presentation have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered, sold or transferred within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act of 1933.

This presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "plans", "goal", "target", "aim", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future and may be beyond genedrive's ability to control or predict, and future events and circumstances can cause results and developments to differ materially from those anticipated. Nothing in this presentation should be construed as a profit forecast. Forward-looking statements are not guarantees of future performance and hence may prove to be erroneous. Other than in accordance with its legal or regulatory obligations (including under the AIM Rules for Companies, Market Abuse Regulation and the Disclosure Guidance and Transparency Rules), genedrive does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

This presentation has been prepared without reference to your particular investment objectives, financial situation, taxation position and particular needs. It is important that you view this presentation in its entirety. If you are in any doubt in relation to these matters, you should consult your stockbroker, bank manager, solicitor, accountant, taxation adviser or other independent financial adviser (where applicable, as authorised under the Financial Services and Markets Act 2000).

GENEDRIVE PLC (LSE : GDR):

- Genedrive® is a proven point of care (POC) molecular diagnostic technology platform
- Significant competitive advantages for target applications
- Accelerating commercial progress post period end

Two new at-launch revenue opportunities:

1. World's first commercial Antibiotic Induced Hearing Loss system (Genedrive MT-RNR1 ID Kit)
2. Rapid POC Covid-19 molecular testing system (Genedrive COV19-ID Kit)

Portfolio of products and advancing pipeline



THE GENEDRIVE® TECHNOLOGY PLATFORMS



Rapid Results where needed
- Technology at your fingertips

Ease of Use
- Single use, disposable reagent cartridge
- Original Single Push button operation
- New touchscreen system to support ICU applications

Versatile platform to build upon
- Same instrument technology is used across a range of applications

Affordable

Extensively Performance Validated

SHORT AND MEDIUM TERM REVENUE TO BE DRIVEN BY COVID AND AIHL

AIHL

- At launch novel Point of Care genetic test for neonatal acute care setting
- Attractive market, product unique to genedrive

COV-2 POC

- Rapid molecular LAMP product with performance differentiating features

Other Assays

- Assays for HCV, Bioplex and high throughput COV-19
- On market but no underpinned revenue forecasts

Future Development

- Focus on markets with attractive margins and potential that utilize Genedrive® systems capabilities in emergency care

genedrive

Antibiotic Induced Hearing Loss (AIHL)

AIHL: Genedrive® MT-RNR1 ID Kit

- New MT-RNR1 system based upon needs of ICU environment and users.
- It has never been possible to rapidly perform the test in an emergency care situation before genedrive's advancement
- Assay developed in 2019 and clinically validated in 2020
- A series of improvements that led to the development of the new Genedrive platform
- Represents the first time **any** commercial point of care molecular test has been performed in a NICU environment

AIHL: PALOH Clinical Study

- Seminal publication and editorial in ***JAMA Pediatrics***.
- Reduces gentamycin related AIHL in neonates
- Clinicians can integrate genetic data into their routine practice in an acute setting
- Our technology is sufficiently rapid to support clinical decision making
- Very good test performance:
  - real-world analytical sensitivity of 100%
  - a specificity of 99.2%
  - accuracy of 99.2%.
  - performance rate of 94.3%

JAMA®

Pediatrics paper supporting implementation of AIHL in neonatal wards

21 March 2022

AIHL – Anticipated route to adoption

Pilot study → Clinical write-up → 1st site adopter → Pioneering adopters → Clinical guidelines → Widespread NHS adoption **+12mths**

- Study completed in Nov-21 - all valid tests confirmed as 100% accurate using genetic sequencing
- Following the study, Manchester NHS adopting the test and acting as reference site for future settings.
- Commercial revenue begins new NHS financial year (April)
- Expecting local NHS collaboration for adoption in NHS in the North West region
- Inspiration Healthcare are commencing their promotion and sales activity with these NHS targets more broadly
- KOL and academic support will be pushed to promote the test for inclusion in clinical care guidelines

genedrive

Genedrive® COV19-ID kit

PRODUCT: GENEDRIVE® SARS COV-2 ID KIT

- CE marked in December 2021 and CTDA applied for shortly thereafter
- 7.5-17 minute test time = faster than competitive systems
- No viral extraction = avoids complexity
- Simple workflow (similar to lateral flow antigen test procedure)
- Multigene gene test target = reduces potential impact of variants
- Manufacturing transition = higher scale and reduced costs
- Initial chemistry performance data on contrived specimens of 100% sensitivity and specificity





SWAB PATIENT

DISPENSE INTO GENEDRIVE CARTRIDGE

INSERT CARTRIDGE

(+) as little as 7.5 minutes

GENEDRIVE® SARS COV-2 ID KIT | TARGETED LAUNCH APPROACH

Opportunities leveraging speed to result

7.5 mins



17 mins

- Distributors signed end February covering Spain, Portugal, Oman and the United Arab Emirate
- First sold shipments commenced in 2nd week March
- Initial focus of distributors aligns with our original expectations – pharmacies, insurers, hospitals, government offices
- Performance Claims expanded to include asymptomatic patients
- CTDA application is under review–no anticipated timelines
- Demand can be more accurately determined in the new few months – COVID growing in selected countries
- Secured second scalable assay manufacturer that can be used when needed
- Second Genedrive® instrument supply

genedrive

Future Development

Future development

- AIHL demonstrates the capabilities and possibilities offered by Genedrive implementation in urgent case settings
- Development focus will be on fast, accurate and affordable tests for opportunities in developed markets and emergency care –similar workflow to AIHL and Covid POC
- Range of pharmacogenomic applications that can be used to asses patients suitability for specific drug types or doses.

Stroke markers and antiplatelet guided therapy

- PALOH demonstrates Genedrive® opportunities and capabilities in acute/urgent care environments.
- Emergency admission for cardiac events has many similarities in terms of users, timeframes, and clinical decision making for a diagnostic test
- Drugs such as Clopidogrel can prevent further strokes or cardiac events can be highly effective, or not effective at all (15-20% patients), depending on the genetic profile of the patient.
- Very large opportunities – for example, over 32 million antiplatelet items were prescribed in 2020/21 at a total cost to the NHS of over £78M.
- Clopidogrel makes up 32.5% of all antiplatelet prescriptions and is one of the top 5 drugs prescribed globally.
- Existing solutions are not suitable for routine POC test, due to their design, formulation, cost, or speed to result.
- In concert with clinical collaborators at MRI, genedrive have already proven feasibility of rapidly detecting CYP2C19 mutations on the Genedrive® platform.



genedrive

Summary Financials

SUMMARY CASHFLOWS

Cashflow

Cashflow	Dec-21	Dec-20	Jun-21
	£'000	£'000	£'000
Cashflow from operations	(2,674)	(2,897)	(5,237)
Working capital	(211)	(1,220)	(933)
Other	(1)	50	(180)
Underlying cashflow	(2,886)	(4,067)	(6,350)
Settlement of convertibles		(358)	(358)
Proceeds of share issue	6,609		46
Taxation	-	-	1,018
Net cash flow	3,723	(4,425)	(5,644)
Cash at bank b/f	2,574	8,218	5,184
Cash at bank c/f	**6,297**	**3,793**	**8,218**
Underlying monthly burn rate:			
Gross	(481)	(678)	(529)
Adjusted for taxation	(384)	(593)	(444)

Cashflow

- Working capital consumed £0.2m versus £1.2m in 2020 with the prior period being mainly impacted by creditors movements
- Cash at 31 Dec 2021 £6.3m, following £6.6m fund raise
- Post period end £1.2m receipt from HMRC R&D tax credit scheme
- Cash at 25 March 2022 £6.0m
- Underlying cash consumption of £2.9m, or £481k pcm. Adjusting for £1,166 R&D tax credit received (£97 pcm), monthly rate reduces to £384,
- Underlying cash consumption now in line with historic levels following one-off working capital costs in 2020/21

ANTICIPATED NEWS FLOW

<6 Months

- NHS updates on AIHL
- Updates on UK/I site adoptions of AIHL
- CoV-POC sales target updates
- Promotion and launch of AIHL assay in other EU countries

>6 Months

- Update on NICE guidelines for AIHL usage in emergency settings
- Consideration of US launch steps for AIHL
- Stroke marker test progress update and launch date confirmation

genedrive

Thank you.